Avatrombopag for the Treatment of Thrombocytopenia in Pediatric Subjects With Immune Thrombocytopenia for ≥6 Months
Status:
Recruiting
Trial end date:
2025-05-15
Target enrollment:
Participant gender:
Summary
A Phase 3b Study to Evaluate the Efficacy and Safety of Avatrombopag for the Treatment of
Thrombocytopenia in Pediatric Subjects with Immune Thrombocytopenia for ≥6 Months